Avior Wealth Management LLC Purchases 123 Shares of Axon Enterprise, Inc. (NASDAQ:AXON)

Avior Wealth Management LLC grew its stake in shares of Axon Enterprise, Inc. (NASDAQ:AXON) by 4.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,853 shares of the biotechnology company’s stock after purchasing an additional 123 shares during the period. Avior Wealth Management LLC’s holdings in Axon Enterprise were worth $737,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of AXON. HB Wealth Management LLC raised its holdings in Axon Enterprise by 3.9% in the fourth quarter. HB Wealth Management LLC now owns 1,139 shares of the biotechnology company’s stock worth $294,000 after buying an additional 43 shares during the last quarter. UMB Bank n.a. boosted its position in shares of Axon Enterprise by 11.0% in the fourth quarter. UMB Bank n.a. now owns 444 shares of the biotechnology company’s stock worth $115,000 after purchasing an additional 44 shares during the period. CWM LLC boosted its position in shares of Axon Enterprise by 1.8% in the third quarter. CWM LLC now owns 2,669 shares of the biotechnology company’s stock worth $531,000 after purchasing an additional 46 shares during the period. Greenleaf Trust lifted its holdings in shares of Axon Enterprise by 3.6% in the third quarter. Greenleaf Trust now owns 1,540 shares of the biotechnology company’s stock worth $306,000 after buying an additional 54 shares in the last quarter. Finally, Czech National Bank lifted its holdings in shares of Axon Enterprise by 0.4% in the fourth quarter. Czech National Bank now owns 12,336 shares of the biotechnology company’s stock worth $3,187,000 after buying an additional 54 shares in the last quarter. 79.08% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

AXON has been the topic of a number of recent research reports. Barclays upped their price target on shares of Axon Enterprise from $296.00 to $308.00 and gave the company an “overweight” rating in a research note on Thursday, February 29th. JPMorgan Chase & Co. increased their target price on shares of Axon Enterprise from $330.00 to $365.00 and gave the stock an “overweight” rating in a report on Thursday, April 11th. StockNews.com lowered shares of Axon Enterprise from a “buy” rating to a “hold” rating in a research report on Thursday, March 14th. Morgan Stanley increased their price objective on shares of Axon Enterprise from $250.00 to $285.00 and gave the company an “equal weight” rating in a research report on Wednesday, February 28th. Finally, Needham & Company LLC raised their price target on shares of Axon Enterprise from $315.00 to $400.00 and gave the stock a “buy” rating in a research report on Wednesday, April 10th. Two analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat, Axon Enterprise has an average rating of “Moderate Buy” and an average price target of $312.64.

Axon Enterprise Trading Down 0.2 %

Shares of AXON opened at $299.82 on Thursday. Axon Enterprise, Inc. has a 52-week low of $175.37 and a 52-week high of $329.87. The company has a quick ratio of 2.66, a current ratio of 3.00 and a debt-to-equity ratio of 0.42. The firm’s fifty day moving average is $299.84 and its two-hundred day moving average is $257.02. The stock has a market cap of $22.62 billion, a PE ratio of 130.36 and a beta of 0.93.

Axon Enterprise (NASDAQ:AXON) last released its earnings results on Tuesday, February 27th. The biotechnology company reported $0.77 earnings per share for the quarter, beating the consensus estimate of $0.48 by $0.29. The company had revenue of $432.14 million during the quarter, compared to the consensus estimate of $418.97 million. Axon Enterprise had a return on equity of 14.11% and a net margin of 11.14%. Research analysts forecast that Axon Enterprise, Inc. will post 2.43 earnings per share for the current fiscal year.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.